Inventor
LIVERTON NIGEL J
US45 patents
⚠️ This page may combine multiple inventors who share the name “LIVERTON NIGEL J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MERCK & CO INC
24 patentsUS5859041AJan 12, 1999
Substituted imidazoles having cytokine inhibitory activity
MERCK & CO INC135 citations98
US5717100AFeb 10, 1998
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
MERCK & CO INC116 citations98
US7470664B2Dec 30, 2008
HCV NS3 protease inhibitors
MERCK & CO INC81 citations97
US5837719ANov 17, 1998
2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
MERCK & CO INC77 citations96
US5792778AAug 11, 1998
2-substituted aryl pyrroles, compositions containing such compounds and methods of use
MERCK & CO INC63 citations96
US6083949AJul 4, 2000
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
MERCK & CO INC28 citations93
US6870055B2Mar 22, 2005
Isoquinolinone potassium channels inhibitors
MERCK & CO INC28 citations92
US6376530B1Apr 23, 2002
Cyclic amidines useful as NMDA NR2B antagonists
MERCK & CO INC22 citations92
US6316474B1Nov 13, 2001
2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
MERCK & CO INC43 citations92
US6207687B1Mar 27, 2001
Substituted imidazoles having cytokine inhibitory activity
MERCK & CO INC21 citations92
US6319944B1Nov 20, 2001
Aryl amidines, compositions containing such compounds and methods of use
MERCK & CO INC21 citations90
US7592360B2Sep 22, 2009
3-fluoro-piperidines as NMDA/NR2B antagonists
MERCK & CO INC18 citations84
US6403596B1Jun 11, 2002
Substituted pyridones having cytokine inhibitory activity
MERCK & CO INC14 citations84
US7259157B2Aug 21, 2007
N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
MERCK & CO INC12 citations83
US7053089B2May 30, 2006
N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
MERCK & CO INC13 citations82
US6492516B1Dec 10, 2002
Compounds having cytokine inhibitory activity
MERCK & CO INC9 citations74
US7217716B2May 15, 2007
N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
MERCK & CO INC8 citations72
US7196095B2Mar 27, 2007
(Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
MERCK & CO INC8 citations71
US6838291B2Jan 4, 2005
Radioligand and binding assay
MERCK & CO INC8 citations71
US6767908B2Jul 27, 2004
Substituted imidazoles having cytokine inhibitory activity
MERCK & CO INC4 citations63
US6602872B1Aug 5, 2003
Substituted pyridazines having cytokine inhibitory activity
MERCK & CO INC1 citations52
US6214823B1Apr 10, 2001
Benzodiazepine derivatives as antiarrhythmic agents
MERCK & CO INC1 citations52
US6291457B1Sep 18, 2001
Compounds having cytokine inhibitory activity
MERCK & CO INC1 citations51
US6440976B2Aug 27, 2002
Iminopyrimidine NMDA NR2B receptor antagonists
MERCK & CO INC0 citations42
MERCK SHARP & DOHME
8 patentsUS7973040B2Jul 5, 2011
Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
MERCK SHARP & DOHME40 citations96
US8377874B2Feb 19, 2013
HCV NS3 protease inhibitors
MERCK SHARP & DOHME9 citations84
US7879797B2Feb 1, 2011
HCV NS3 protease inhibitors
MERCK SHARP & DOHME15 citations84
US8377873B2Feb 19, 2013
HCV NS3 protease inhibitors
MERCK SHARP & DOHME9 citations82
US11655216B2May 23, 2023
Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use
MERCK SHARP & DOHME0 citations49
US10961215B2Mar 30, 2021
N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use
MERCK SHARP & DOHME0 citations49
US10894775B2Jan 19, 2021
Piperidine derivatives as liver X receptor beta agonists, compositions, and their use
MERCK SHARP & DOHME0 citations48
US9738661B2Aug 22, 2017
HCV NS3 protease inhibitors
MERCK SHARP & DOHME0 citations41
LIVERTON NIGEL J
4 patentsUS8828930B2Sep 9, 2014
Hepatitis C virus NS3 protease inhibitors
LIVERTON NIGEL J8 citations83
US8309540B2Nov 13, 2012
HCV NS3 protease inhibitors
LIVERTON NIGEL J9 citations83
US8138164B2Mar 20, 2012
HCV NS3 protease inhibitors
LIVERTON NIGEL J11 citations83
US8461107B2Jun 11, 2013
HCV NS3 protease inhibitors
LIVERTON NIGEL J12 citations82
MCCOMAS CASEY C
3 patentsUS9265773B2Feb 23, 2016
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
MCCOMAS CASEY C8 citations82
US9573939B2Feb 21, 2017
Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
MCCOMAS CASEY C6 citations71
US9549917B2Jan 24, 2017
Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
MCCOMAS CASEY C1 citations50